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Abstract
Cerebral malaria continues to be a difficult to treat complication of Plasmodium falciparum infection in children. We have
shown that platelets can have major deleterious immune functions in experimental cerebral malaria (ECM). One of the
platelet derived mediators we have identified as particularly important is platelet factor 4/CXCL4. Our prior work
demonstrated that PF4
2/2 mice are protected from ECM, have reduced plasma cytokines, and have reduced T-cell
trafficking to the brain. We now show that PF4 drives monocyte cytokine production in a Kruppel like factor 4 (KLF4)
dependent manner. Monocyte depleted Plasmodium berghei infected mice have improved survival, and KLF4 is greatly
increased in control, but not monocyte depleted mice. PF4
2/2 mice have less cerebral monocyte trafficking and no change
in KLF4 expression. These data indicate that PF4 induction of monocyte KLF4 expression may be an important step in the
pathogenesis of ECM.
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Introduction
Cerebral malaria is a major complication of Plasmodium
falciparum infection in children. In a recent study 33% of children
admitted to a hospital in Kenya were reported to have had
malaria, and of these, 47% had neurologic symptoms [1]. In 2002
alone there were an estimated 515 million clinical episodes of
acute P. falciparum infection worldwide, mainly affecting children
less than 5 years of age [1]. Cerebral Malaria (CM) is the result of
a combination of vascular and immune system dysfunction. Brain
tissue from patients that die of CM reveals multifocal capillary
obstruction with parasitized red blood cells (RBC), platelets and
leukocytes [2]. Several hypotheses have attempted to explain the
noted pathology, but most now include cell adhesion to the
endothelium or direct infected RBC (iRBC) interactions with
platelets as promoting pro-thrombotic immune responses, result-
ing in further vascular inflammation, immune stimulation and
obstruction of cerebral capillaries [2].
In addition to their vital role in hemostasis, platelets are also
active in inflammation [3]. Platelet granules contain many
inflammatory and adhesion molecules that are either released
or expressed upon activation and platelets can initiate interac-
tions with quiescent endothelial and immune cells [4]. Platelets
are known to contribute to the progression of diverse vascular
and inflammatory diseases including the pathogenesis of CM
[5–7]. Platelet and RBC aggregates are found in cerebral blood
vessels of individuals with fatal CM [7,8]. Cytokines, such as
TNFa and IL-6, are also greatly increased in the disease course
and cytokine dysregulation has a major role in the progression of
CM. TNFa can increase platelet binding to the brain
microvasculature in ECM [9], further demonstrating this
important interplay between platelets and immune responses in
cerebral malaria.
We have demonstrated using the Plasmodium berghei ANKA
mouse model of experimental cerebral malaria (ECM) that
platelets are activated by direct CD36 dependent interactions
with Plasmodium iRBCs leading to increased circulating levels of
platelet factor 4 (PF4/CXCL4) [10]. PF4
2/2 mice have greatly
improved survival and reduced plasma chemokine and cytokine
concentrations [10]. A prominent function of chemokines is to
promote the chemotaxis and activation of leukocytes. PF4 was the
first described CXC class chemokine and is abundant in platelet
granules (about 25% of total alpha granule protein content)
[11,12]. PF4 can exert effects on monocytes, neutrophils, NK cells,
and T-cells through poorly defined mechanisms [13,14] and we
have described a reduction in T-cell trafficking in Plasmodium berghei
(P. berghei) infected PF4
2/2 mice compared to WT mice [10].
Although chemokine signaling is an important mediator of CM
[15,16], there has been little examination of the role for platelet
derived chemokines. Basal PF4 concentration in human plasma is
2–20 ng/mL, but in acute thrombosis has been reported elevated
over 1000 times to 5–10 mg/mL [11,17]. During acute P.
falciparum infection in humans plasma concentrations of PF4 are
also elevated [18] and we have shown that plasma PF4 is greatly
increased in ECM (over 1 mg/mL), demonstrating a potentially
significant role for platelets and PF4 in mediating malaria
associated immune dysregulation.
The role of T-cells in ECM is well explored, but monocytes/
macrophages have received much less attention despite a
potentially important role in driving innate and initiating acquired
immune responses. Platelet-monocyte interactions are well estab-
lished in other vascular inflammatory diseases such as atheroscle-
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10413Figure 1. PF4 Stimulates Monocyte Activation. A. Dose Response. Monocytes were incubated with PF4 for 48 hrs and TNFa measured by ELISA
(n=4 6 S.D. *P,0.03 vs 0). B. Monocytes were treated with control PBS, 1 mg/mL PF4, or 50 U/mL heparin prior to PF4 as control. TNF-a was
measured 48 hrs later (n=4 6 S.D. *P,0.01 vs Control). C. IL-6. IL-6 was measured 48 hrs after PF4 by ELISA (n=4 6 S.D. *P,0.01 vs control). D.
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PF4 can induce monocyte cytokine production [22]. Kruppel like
factor 4 (KLF4) is a transcription factor necessary for monocyte
differentiation and acquisition of an inflammatory phenotype
[23–25]. We now demonstrate both in vitro and in ECM that PF4
increases monocyte cytokine stimulation, which is dependent at
least in part, on PF4 increasing the expression of the transcription
factor KLF4.
Results
PF4 induces monocyte cytokine production
PF4 has been described as a mediator of monocyte differenti-
ation and cytokine production [26]. A major outcome of monocyte
activation is elaboration of inflammatory mediators such as TNFa
and IL-6, each of which has been shown to be necessary or
associated with cerebral malaria [8,27–30]. Our prior studies have
shown that in ECM PF4
2/2 mice have greatly reduced plasma
TNFa compared to WT mice [10]. To demonstrate that PF4
stimulates monocyte TNFa production we isolated primary
marrow derived monocytes from mice, incubated these cells with
physiologic concentrations of recombinant PF4 for 48 hrs (we
have shown that PF4 levels are greater than 1 mg/mL in ECM
[10]) and TNFa production was measured in the supernatant
using an ELISA. PF4 drives increased monocyte TNFa produc-
tion (Figure 1A). To demonstrate that this is a direct PF4 effect,
and not the result of recombinant protein contamination, we
incubated primary mouse monocytes with control buffer, 1 mg/
mL of recombinant PF4, or PF4 in the presence of 50 U/mL of
heparin to neutralize the PF4. PF4 again greatly increased TNFa
production, but this was inhibited in the presence of heparin
(Figure 1B). Similarly, PF4 also increased mouse monocyte IL-6
production (Figure 1C).
Platelets can stimulate monocytes by both contact dependent and
independent mechanisms [4,19,20]. To demonstrate the importance
of PF4 in platelet releasate mediated monocyte activation, we isolated
WT and PF4
2/2 mouse platelets and incubated each platelet type
with 0.5 U/mL of thrombin for 10 mins to fully activate, before
neutralizing with an equal concentration of hirudin. Platelet releasate
was then isolated and incubated with monocytes for 24 hrs at a
physiologic ratio of releasate source platelets to monocytes (releasate
from2610
6platelets added to 1610
5monocytes). IL-6was measured
using an ELISA. PF4
2/2 platelet releasate significantly increased
monocyte IL-6 production (Figure 1D grey bar). However, WT
platelet releasate induced a much greater increase in monocyte IL-6
production (Figure 1D, black bar). These data directly indicate that
PF4 has a major role in platelet induced monocyte cytokine
production either alone, or in combination with other platelet
immune mediators that it may complex with. To confirm that these
data were not an artifact of mouse primary monocyte isolation, the
human monocyte cell line, THP-1 cells, were incubated with 1 mg/
mL of human platelet isolated PF4. PF4 also induced an increase in
THP-1 TNFa production (Figure 1E). These data demonstrate that
concentrations of PF4 relevant to ECM induce monocyte cytokine
production, including IL-6 and TNFa.
PF4 increases monocyte KLF4 expression and activity
KLF4 is a transcription factor vital to monocyte develop-
ment, differentiation, and pro-inflammatory phenotype [23,25].
KLF4
2/2 mice are embryonic lethal and mice reconstituted with
KLF4
2/2 bone marrow have greatly reduced monocyte numbers
[23]. To begin to determine if PF4 mediated effects on monocytes
are KLF4 dependent, we isolated mouse monocytes and incubated
these cells with control PBS, PF4, or PF4 after heparin pre-
treatment. KLF4 mRNA expression was then determined
24 hours later by quantitative Real-Time PCR (qRT-PCR). PF4
significantly increased KLF4 mRNA (Figure 2A). This was
confirmed by Western blot on monocytes treated the same way
and demonstrating that PF4 also increased KLF4 protein
expression (Figure 2B). (These experiments were also performed
after de-glycosylating monocytes with chondroitnase ABC, but the
treatment itself induced KLF4 expression, perhaps the result of the
cleavage establishing downstream signaling and KLF4 expression).
We also incubated THP-1 cells with 1 mg/mL of PF4 and at 1, 24,
and 48 hrs determined KLF4 expression by Western blot. KLF4
expression was increased 24 and 48 hrs of incubation with PF4
(Figure 2C and quantification Figure 2D; no change at 72 hrs
compared to control not shown). These data demonstrate that PF4
drives an increase in KLF4 expression.
Because KLF4 is a transcription factor, PF4 induced increase in
KLF4 expression is expected to increase KLF4 DNA binding. To
demonstrate this, THP-1 cells were incubated with 1 mg/mL of
PF4 and 0, 2, 6 and 24 hrs later nuclear extracts were isolated for
chromatin immunoprecipitation (ChIP). DNA was prepared and
PCR amplified using primers for the known KLF4 binding
promoter sequence of the bradykinin 2 receptor promoter.
Control kit DNA and control total spleen cDNA were used as
positive controls (far right). At 24 hrs post PF4 addition KLF4
immunoprecipitates with genomic DNA, but not at the early time
points we examined (Figure 3A). Because PF4 drives an increase in
IL-6 and TNFa production, we also amplified immunoprecipitat-
ed DNA with primers for the promoter regions for both IL-6 and
TNFa. IL-6 promoter DNA immunoprecipitated with KLF4
(Figure 3B), but not TNFa (not shown). This indicates that PF4
may directly increase IL-6 through KLF4, but PF4 induced
increase in TNFa is indirect/downstream or through other
transcription factor pathways.
Having established that PF4 induced monocyte cytokine
signaling and KLF4 expression, we wanted to demonstrate the
two events were functionally linked. To do so, we treated THP-1
cells with control siRNA or siRNA specific for KLF4 to
knockdown KLF4 expression (Supplementary Figure S1). We
then treated the cells with buffer or 1 mg/mL of PF4 and measured
IL-6 production by ELISA 24 hrs later. PF4 increased IL-6
production in control siRNA treated cells, but had no effect on IL-
6 production from KLF4 specific siRNA treated cells (Figure 3C).
These data demonstrate that PF4 induction of monocyte
activation is KLF4 dependent.
PF4 increases monocyte KLF4 in ECM
We next sought to clearly demonstrate that monocytes have a
key role in the pathogenesis of ECM. Mice infected with P.
berghei ANKA were injected intraperitoneal with either control
PBS, IgG, or anti-CD14 antibody (days 1 and 5 post infection) to
clear monoctyes from the circulation without affecting other blood
cells (complete blood counts in Supplementary Figure S2). Mice
were then monitored for survival. Monocyte depleted mice had
Platelet PF4 increases monocyte IL-6 production Mouse monocytes were incubated with resting WT platelet supernatant and activated WT or PF4
2/2
platelet releasate. 24 hrs later IL-6 was measured (n=4 6 S.D. *P,0.01). E. Human monocyte cell line. THP-1 cells were incubated with 1 mg/mL of
PF4 or PF4 in the presence of heparin and TNFa production measured (n=3 6 S.D. *P,0.01 vs Control).
doi:10.1371/journal.pone.0010413.g001
PF4 Increases KLF4 in ECM
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10413Figure 2. PF4 Increases Monocyte KLF4 Expression. A. Mouse monocytes were incubated with 1 mg/mL of PF4 and KLF4 mRNA was quantified
by qRT-PCR (n=4; 6 S.D. *P,0.05 vs Control). B. KLF4 immunoblot (n=4 pooled samples). C. KLF4 Time Course. THP-1 cells were incubated with
1 mg/mL of PF4 and at each time point KLF4 expression was determined by immunoblot (representative image). D. Western blot quantification of
KLF4 (n=3; 6 S.E.M *P,0.05 vs Time 0).
doi:10.1371/journal.pone.0010413.g002
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PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10413significantly improved survival (Figure 4A) confirming that
monocytes are important in the pathogenesis of ECM.
Our in vitro data demonstrated that KLF4 is important in PF4
mediated monocyte activation. To demonstrate that KLF4 is
increased in vivo during ECM we collected spleens from control
IgG and anti-CD14 antibody treated mice on day 4 post-infection
and isolated mRNA to quantify KLF4 expression by qRT-PCR
(spleens are an important reservoir for monocytes that undergo
trafficking to sites of inflammation [31]. Infected control IgG
treated mice had a large increase in KLF4 mRNA expression
compared to uninfected mice (Figure 4B). However, the increase
in KLF4 expression is much less in infected monocyte depleted
mice demonstrating that the increase in KLF4 during ECM is in
part monocyte specific (Figure 4B; no change in uninfected IgG
and CD14 antibody treated mice was seen, Supplementary Figure
S4). This was confirmed on the protein level by pooling spleens
from these mice then immunoprecipitating and immunoblotting
for KLF4 (Figure 4C and Supplementary Figure S3).
PF4 mediates an increase in KLF4 in vivo during ECM
Our prior work has demonstrated that PF4
2/2 mice have
improved ECM survival and reduced plasma cytokines. This in
vitro data demonstrated that PF4 increased monocyte KLF4
expression. To determine whether PF4 has a role in driving KLF4
expression during ECM we isolated spleens from infected WT and
PF4
2/2 mice on day 4 post-infection and quantified KLF4
expression by qRT-PCR. Similar to our results in Figure 4, WT
mice had a greater than 4 times increase in KLF4 mRNA
expression as compared to control uninfected mice (Figure 5A).
However, PF4
2/2 mice had very little change in KLF4 expression
(Figure 5A), demonstrating a PF4-KLF4 signaling axis is present
and functional in ECM.
Our prior work demonstrated that P. berghei infected PF4
2/2
mice have reduced T-cell trafficking to the brain as compared to
WT infected mice [10]. We have now found similar results with
monocyte trafficking. WT and PF4
2/2 mice were infected and on
day 5 post infection brain mononuclear cells were isolated as we
have described [10] and the total number of monocytes quantified
using a mouse automated hematologic analyzer. Infected WT
mice had a much greater number of brain monocytes compared to
PF4
2/2 mice (Figure 5B). To further demonstrate this is a direct
PF4 effect on cell trafficking, mice were given GFP positive
monocytes on day 4 post infection. Twelve hours later brains were
collected from the mice, mononuclear cells isolated, and GFP
positive cells quantified as a percent of total mononuclear cells by
flow cytometry. WT mice had significantly greater monocyte
trafficking to the brain as compared to PF4
2/2 mice (Figure 5C)
demonstrating an important role for PF4 in driving monocyte
recruitment in ECM.
Taken together these data demonstrate that PF4 increases
monocyte activation and KLF4 expression in vitro and in vivo in a
cerebral malaria disease model.
Discussion
Platelets are dynamic cells with important roles in hemostasis
and inflammation. A more complete appreciation for platelet
immune functions continues to become unraveled [3]. Work from
our lab has demonstrated an important role for platelets, and
platelet derived PF4, in T-cell recruitment and the pathogenesis of
ECM [10]. This work now demonstrates that PF4 also helps drive
an early innate immune response to Plasmodium infection by
activating monocytes in a KLF4 dependent manner.
An important role for platelets in the pathogenesis of cerebral
malaria is an area of increasing interest, and perhaps confusion.
Platelets have been described to have diverse roles in vascular
biology, likely a result of the diversity of inflammatory mediators
platelets secrete or express upon activation. For example, platelets
have been described to support angiogenesis [32], yet PF4 is a
major platelet chemokine that has been described as an inhibitor
of angiogenesis [11,33,34]. Our work, and that of many other
investigators, has demonstrated that platelets have a deleterious
role in ECM [5,7,8,10,27,35]. However, intriguing recent work
has indicated that the role of platelets may be dependent on the
manifestation of Plasmodium infection by demonstrating that
platelets can contribute to the killing of intraerythrocytic parasites
in uncomplicated malaria [36]. These studies all point out the
important complexity of platelet mediated signaling pathways and
the need for further study to better understand the role of platelets
in malaria pathogenesis.
PF4 makes up approximately 25% of the alpha granule content
and reaches plasma concentrations of greater than 1 mg/mL in
ECM [10,11,34]. PF4 has been most studied in the context of
heparin induced thrombocytopenia during which PF4-heparin
complexes are immunogenic and lead to antibody mediated
platelet destruction [37–39]. Immune roles for PF4 are less well
described, but likely more important given the global prevalence of
vascular inflammatory diseases ranging from atherosclerosis to
cerebral malaria. Elimination of PF4 reduces atherosclerotic lesion
size in ApoE
2/2 mice and disruption of PF4 and RANTES
complexes can also reduce atherosclerosis in this mouse model
[40,41]. PF4 may also have a seemingly contradictory role by
improving survival after LPS challenge [42]. Our work has shown
that in the context of ECM PF4 has a deleterious role in driving
immune stimulation, including monocyte activation.
The Kruppel like family of transcription factors have major
disease relevance, particularly in cardiovascular pathologies [43–
46]. The KLF family helps direct cell proliferation, differentiation,
and survival in numerous tissue types ranging from gastrointestinal
to immune cells [47–49]. The importance of KLF function is
underscored by relatively small changes in KLF expression having
large functional changes. For example hemizygous KLF2 mice
have altered atherosclerotic risk and haploinsufficiency of KLF4
results in increased intestinal tumor formation [50,51]. KLF4 can
be a transcriptional activator or repressor depending on the
promoter context and other transcription factor interactions
[48,52]. KLF4 is a critical transcription factor in controlling
monocyte differentiation and is also essential for inflammatory
monocyte development [25]. Over expression of KLF4 in pre-
monoctye cell lines drives cell maturation to monocytes, and
forced expression of KLF4 in myeloid progenitors or hematopoi-
etic stem cells leads to monocyte differentiation [23,24]. Our work
demonstrates that PF4 leads to an upregulation of monocyte
KLF4 expression and cytokine production in vitro and in vivo.
Figure 3. PF4 Stimulates KLF4 Activity. A. PF4 induces KLF4 DNA binding. THP-1 cells were incubated with 1 mg/mL of PF4 and at each time
point nuclear extracts isolated for ChIP. DNA was prepared and PCR amplified with primers for the known positive control bradykinin 2 receptor
promoter. Control DNA and control total spleen cDNA were used as positive controls (far right). B. IL-6 Promoter Binding. KLF4 ChIP DNA was
prepared and PCR amplified with primers for the IL-6 promoter. C. KLF4 mediates PF4 induced monocyte stimulation. THP-1 cells were treated with
control siRNA or KLF4 siRNA and incubated or not with 1 mg/mL PF4. IL-6 was measured by ELISA (n=4 6 S.D. *P,0.01 vs control).
doi:10.1371/journal.pone.0010413.g003
PF4 Increases KLF4 in ECM
PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10413PF4 Increases KLF4 in ECM
PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10413Elaboration of cytokines is a major event in the development of
cerebral malaria. Targeting PF4 induced KLF4 signaling networks
may therefore be a target in interrupting the inflammatory
pathways that lead to ECM.
Because KLF4 is vital in the development and differentiation of
stem cells, KLF4
2/2 mice are embryonic lethal. Reconstitution
of WT mice with fetal derived KLF4
2/2 heme progenitor cells is
also problematic, as it results in mice with greatly suppressed
monocyte numbers [23]. Unfortunately this means that direct
evidence for the importance of PF4-KLF4 monocyte signaling in
ECM is lacking from our work. However, our data clearly
demonstrate that PF4 leads to monocyte activation that is at least
in part a KLF4 dependent process. Infected PF4
2/2 mice had
approximately the same amount of KLF4 mRNA expression as
uninfected mice, indicating that KLF4 is increased in ECM in a
PF4 dependent manner. Because PF4
2/2 mice are protected
from ECM and have less monocyte trafficking this provides a
strong link to the importance of PF4 driven KLF4 expression in
ECM.
Like all disease model systems, the mouse model of cerebral
malaria is imperfect. However, it does recapitulate many of the
important immune aspects of cerebral malaria and is the best
model system available to study the early steps in cerebral malaria
pathogenesis [2,53]. Although the parasite burden does not reach
those levels found in humans, much of the immune cytokine
dysfunction and brain histopathology are recapitulated [53]. In
particular, a potential vital role for platelets in driving cerebral
malaria and the presence of platelet aggregates in brain lesions has
been demonstrated in both human cerebral malaria and the
mouse model [6,7].
Platelets are major mediators of the immune response,
particularly in cerebral malaria. Despite much investigation
cerebral malaria continues to be a persistent problem leading to
great morbidity and mortality in the developing world. A better
understanding of platelets and platelet derived mediators in ECM
may lead to the development of new therapeutic strategies to treat
this persistent clinical problem in much of the world.
Materials and Methods
Ethics Statement
All animal studies were performed at an AAALAC accredited
institute using methods and guidelines approved by University of
Rochester Animal Care and Use Committee that comply with
United States national guidelines for the use of animals in
research.
Reagents
ELISA kits, KLF4 chromatin immunoprecipitation kit and
recombinant mouse PF4 were purchased from R & D systems.
Human PF4 was purchased from Haematologic Technologies.
KLF4 and actin antibodies were purchased from Abcam.
CD14 antibody was purchased from eBioscience. SiRNA
and actin antibody were purchased from Santa Cruz Biotech-
nologies. CX3CR-GFP mice were purchased from Jackson
Labs. Heparin, thrombin and hirudin were purchased from
Sigma.
Mouse infections
PF4
2/2 mice are on a C57Bl6 background as we have used and
reported in a past publication [10]. Mice were infected with P.
berghei ANKA by injection of approximately 0.5610
6 parasites
intraperitoneal (IP).
In Vitro Monocyte Culture
For in vitro monocyte studies, C57Bl6/J mouse femurs were
flushed to isolate bone marrow, single cell suspensions formed and
red blood cells lysed with ACK lysis buffer. Monocytes were then
isolated by negative selection (StemCell Technology) and incu-
bated in DMEM with 5% FBS. THP-1cells were also maintained
in the same media. GFP positive mouse monocytes were isolated
using the same methods.
PCR and Western blots
Cell or tissue samples for qRT-PCR were collected and stored
in RNA Later (Ambion) solution at 280uC until RNA isolation
using Trizol. 100 ng of RNA was used for Reverse Transcriptase
(RT) reaction to make cDNA using Applied Biosystems High
Capacity cDNA RT Kits and cDNA used for Real Time
amplification analysis using a BioRad MyiQ Single Color Real
Time PCR Detection system and Taqman Gene Expression
mastermix (Applied Biosystem). The probes used were ordered
from Applied Biosystems (Mm00607939_s1 mouse Actb,
Mm00516104_m1 mouse KLF4, Hs99999903_m1 Human Actb,
Hs00350836_m1 Human KLF4).
Western blot quantification was performed using a Bio-Rad Gel
Doc Imaging Station and software.
KLF4 ChIP was performed using a KLF4 specific kit and
amplification of bradykinin 2 receptor was with primers provided
by the kit. Primers for amplification of IL-6 were; forward
AGTGGTGAAGAGACTCAGTG and reverse GGCAGAAT-
GAGCCTCAGA [54].
Platelet Releasate Preparation
Washed WT and PF4
2/2 mouse platelets were isolated and
resuspended in Tyrode’s buffer as we have described [55] and
activated with 0.5 U/mL of thrombin (Sigma) for 10 mins before
neutralization with hirudin (Sigma) and centrifugation. Isolated
supernatant contained platelet releasate. Releasate from 2610
6
WT or PF4
2/2 platelets was then added to 1610
5 monocytes for
24 hrs.
Brain Mononuclear Cell Isolation
Brain mononuclear cells were isolated by removing brains and a
single cell suspension obtained by grinding the tissue and mincing
it with a razor blade in Dulbecco modified Eagle medium with
10% fetal bovine serum while on ice. Cell suspensions were placed
in 15-ml conical tubes and Percoll (Sigma) added to a final
concentration of 30%. One mL of Percoll was underlaid and cells
spun at 1,3006g for 30 min at 4uC. Cells at the interface were
isolated, washed twice, resuspended in Tyrode’s buffer, and flow
cytometry performed. Brain monocyte counting was performed
using an Abaxis Veterinary Diagnostics VetScan HM5 Hematol-
ogy System automated analyzer.
Figure 4. Monocytes are Important in the Development of ECM. A. Survival Curve. Mice were monocyte depleted with anti-CD14 antibody
and infected with P. berghei (n=5 *P,0.05 vs IgG). B. Monocytes are a significant source of KLF4 in ECM. mRNA. qRT-PCR for KLF4 was performed on
spleens of uninfected and infected IgG and anti-CD14 treated mice (n=5, S.D. *P,0.01 vs IgG) C. Protein. Spleen lysates were pooled and
immunoprecipitated with anti-KLF4 antibody prior to KLF4 immunoblot (n=5 mice).
doi:10.1371/journal.pone.0010413.g004
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Figure S1 PF4 increases monocyte KLF4 expression. Blocking
KLF4 by siRNA in THP-1 cells blocks IL-6 in response to PF4.
Western Blot control.
Found at: doi:10.1371/journal.pone.0010413.s001 (1.56 MB TIF)
Figure S2 CBC of control and CD14 antibody treated mice.
Mice were treated with control IgG or anti-CD14 antibody IP and
12 hours later blood was collected for CBC (n=4, *P,0.02).
Found at: doi:10.1371/journal.pone.0010413.s002 (1.56 MB TIF)
Figure S3 KLF4 is increased in P. berghei infected mice. Mice
were infected with P. berghei and on day 5 p.i. spleens were
immunoblotted for KLF4 from infected mice and control
uninfected mice. KLF4 is increased in the spleens of infected
mice (top). Tubulin was used as loading control (bottom).
Found at: doi:10.1371/journal.pone.0010413.s003 (1.56 MB TIF)
Figure S4 KLF4 mRNA is unchanged in uninfected anti-CD14
antibody treated mice compared to control IgG treated mice.
Found at: doi:10.1371/journal.pone.0010413.s004 (1.56 MB TIF)
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